Writing An Rx For Profit?By
Initial public offerings are hot issues, but secondary offerings can spell trouble: The stock usually tumbles. Not so with ProxyMed (PILL), an information-technology company, which made a secondary offering on May 8 of 2 million shares at 6 1/4. The stock shot up to 8 that very day and is now at 10.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.